Targets › GAG
2 programs from 1 company in 28 trials: 18 Phase 2, 7 Phase 3, 2 Phase 4, 1 Phase 1; Infectious disease; next expected readout Mar 2027.
Open in Phaseline: the race on GAG, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Gilead Sciences | Lenacapavir Structural capsid protein inhibitor | CA, CPSF6, GAG, PROT, UNKNOWN, CAPSID | Phase 3 | Pre-Exposure Prophylaxis of HIV Infection; HIV Pre-exposure Prophylaxis; HIV Infections; HIV-1-infection … | Mar 2027 |
| Gilead Sciences | ISL/LEN FDC Fixed-dose combination of nucleotide reverse transcriptase translocation inhibitor and HIV | POLB, GAG | Phase 2 | HIV-1 Infection | Mar 2028 |
HIV-1-infection (10) Pre-Exposure Prophylaxis of HIV Infection (7) HIV-1 Infection (4) HIV Pre-exposure Prophylaxis (2) HIV Infections (1) HIV-1-Infection (1) HIV (1) HIV Prevention (1) Human Immunodeficiency Virus (1)
mixed (1), small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.